ABSTRACT
INTRODUCTION
Given the availability of serial body temperature assessments, time to 129 defervescence was also evaluated as an efficacy outcome. The most abnormal 130 temperature reading for the day was recorded in the case report form.
131
Defervescence was defined as being afebrile for more than 48 hours and the 132 time to defervescence was defined as the midpoint of the interval between the 133 last febrile temperature measure and the first afebrile temperature measure. 
153
Where dose was equal to the total daily dose of tigecycline (100 mg) and CLt is was then tested, first using stratified Kaplan-Meier and then, if significant at a 220 level of α = 0.1, as a covariate in a multivariable model as described below.
221
Other potential predictors of time to defervescence, as described in Table 1 ,
222
were evaluated univariably in a similar manner. All potential predictors deemed 223 significant in a univariable fashion were evaluated using a multivariable Cox 224 mode and backward step-wise elimination (α = 0.05). had monomicrobial and polymicrobial S. pneumoniae infections, respectively.
258
As described earlier, patients were divided into three cohorts (monomicrobial 259 S. pneumoniae, mono-and polymicrobial S. pneumoniae, all patients).
260
Summary statistics for the demographic variables, stratified by cohort, are 261 provided in The frequency distribution histogram for AUC0-24 is provided in Figure 3 .
325
The incidence of the selected dichotomous adverse events examined among 326 the 289 patients in the safety analysis cohort is provided in both sex and AUC0-24 evaluated as categorical variables, is shown in Table 8 . the test-of-cure visit) was too insensitive to capture the drug's benefit, and (4) 393 there was no exposure-response relationship (i.e., the drug lacks benefit) [1] .
395
It is likely that our failure to identify an exposure-response relationship for efficacy 396 in this analysis was due to the first of the above-described reasons. In the current 397 data set, only 7% (5/68) were categorized microbiological treatment failures. change from baseline in total bilirubin is unlikely to be clinically significant. 
